Nektar Q2 2026 Earnings: Phase 3 Spending Rises as Cash and Investments Top $1 Billion

Nektar Therapeutics (NASDAQ: NKTR) reported Q2 2026 revenue of $10.1 million, down from $11.2 million a year earlier, and a basic and diluted net loss of $1.23 per share versus $2.95. For the quarter ended June 30, higher Phase 3 preparation and manufacturing spending widened the operating loss, while interest income and a smaller equity-method investment loss helped the net loss narrow slightly.

Core earnings data

All reported revenue was non-cash royalty revenue related to prior sales of future royalties, rather than commercial sales from Nektar’s clinical pipeline. Total operating costs increased as higher research and development spending more than offset lower general and administrative expenses.

The operating loss widened, but the net loss narrowed by about 2.3% because non-operating results improved. The much larger reduction in loss per share also reflected a weighted average share count that more than doubled.

Pipeline and development milestones

Nektar initiated the first two global registrational trials in the Phase 3 ZENITH AD program in July 2026, shortly after the quarter ended. The atopic dermatitis program will contain three randomized, double-blind, placebo-controlled studies of rezpegaldesleukin. ZENITH AD-1 and AD-2 will enroll patients who have not received biologics or systemic JAK inhibitors, while AD-3 will study previously treated patients.

The company plans to begin a single registrational Phase 3 study in alopecia areata in early 2027. Management’s current development timeline calls for initial Phase 3 readouts in mid-2028 and the first biologics license application for rezpegaldesleukin in 2029.

Nektar also plans to present longer-term rezpegaldesleukin results in atopic dermatitis and alopecia areata at the European Academy of Dermatology and Venereology Congress on October 1, 2026. The alopecia areata presentation will include 52-week results from the Phase 2b REZOLVE-AA study.

Higher R&D widened the operating loss, but non-operating income softened the net loss

R&D expense increased by $9.2 million as Nektar began activities supporting the Phase 3 ZENITH AD program and expanded manufacturing work for rezpegaldesleukin. G&A expense declined by $4.3 million, primarily because of lower legal expenses, but that reduction was not enough to offset the increase in clinical development spending.

Below the operating line, interest income rose to $9.3 million from $2.0 million. That improvement outweighed the increase in non-cash interest expense associated with liabilities from sales of future royalties, helping total non-operating results shift to income of $2.0 million from an expense of $3.2 million. The non-cash loss from Nektar’s Gannet BioChem equity-method investment also declined to $0.3 million from $2.4 million.

These items explain why the operating loss widened while the net loss narrowed slightly. Meanwhile, the increase in weighted average shares from 14.09 million to 33.05 million made the year-over-year improvement in per-share loss substantially larger than the change in total net loss.

Liquidity and balance sheet

Cash and investments in marketable securities totaled $1.023 billion at June 30, 2026, compared with $245.8 million at December 31, 2025. The June balance consisted of $39.3 million in cash and equivalents, $645.1 million in short-term investments, and $339.1 million in long-term investments.

Nektar completed an underwritten common-stock offering in April that generated $373.8 million of gross proceeds. At quarter-end, the company had $1.095 billion in total assets, $192.0 million in total liabilities, and $903.1 million in stockholders’ equity.

Management said the current cash runway extends into Q3 2028, beyond the initial Phase 3 data readouts expected in mid-2028. This places clinical execution and the timing of those readouts at the center of the company’s funding outlook.

Recent insider transactions

The supplied six-month aggregate reports no insider purchases. Separately, the detailed transaction records list eight sales from January through June 2026 and two zero-dollar stock awards in December 2025 among the latest ten entries; these transactions do not, by themselves, establish insiders’ views of the company’s prospects.

Investor risks to watch

• Phase 3 execution: The development timeline depends on trial initiation, enrollment, manufacturing, completion, and data availability proceeding as planned. Delays could affect both the expected mid-2028 readouts and the stated cash runway relationship.
• Clinical and regulatory uncertainty: Rezpegaldesleukin remains investigational. Earlier clinical results do not guarantee successful Phase 3 safety and efficacy findings or regulatory approval.
• Rising development costs: R&D spending increased by about 31% as Phase 3 preparations accelerated. Continued spending without commercial product revenue could increase operating losses as the program advances.
• Revenue quality: Q2 revenue consisted entirely of non-cash royalty revenue related to prior sales of future royalties, so it does not represent cash-generating sales from Nektar’s current drug candidates.
• Larger share base: Weighted average shares more than doubled from the prior-year quarter, making per-share comparisons look more favorable than the modest improvement in the company’s total net loss.

Summary

Nektar’s Q2 2026 results reflect its transition into late-stage development: spending on rezpegaldesleukin increased and the operating loss widened, but improved non-operating income limited the change in net loss. The expanded balance sheet is expected to fund operations through the initial Phase 3 readouts, leaving trial execution, development costs, and the quality and timing of mid-2028 data as the primary issues to monitor.